Core method & policy

How to Calculate ELCR (Excess Lifetime Cancer Risk) from HPHCs for FDA

Answers: “ELCR calculation for tobacco products / HPHC”

Excess Lifetime Cancer Risk (ELCR) is a core toxicological safety metric in a PMTA. It quantifies the incremental cancer risk attributable to a product's Harmful and Potentially Harmful Constituents (HPHCs).

The calculation chain, in plain terms

  1. Start from measured HPHC concentrations (your lab results).
  2. Apply a corrected Inhalation Unit Risk (IUR) library drawn from OEHHA, EPA IRIS and IARC classifications.
  3. Sum across constituents to get Σ ELCR.
  4. Express Σ ELCR as a percentage of the 1R6F reference cigarette so reviewers have an anchored comparison.
  5. Auto-tier the result into FDA's 5-level concern scale.

A worked example from the tool: a candidate returning Σ ELCR of 2.1×10⁻⁴ at 11% of the 1R6F reference falls into a "Low · Tier 2" concern band — a number a reviewer can act on, delivered in minutes rather than after weeks of manual IUR calculation plus external tox review.

Pros vs. cons. Pro: reproducible, auditable, and faithful to the FDA CTP 2024-06 memo, with the corrected IUR library maintained for you. Con: ELCR is only the toxicology slice of a PMTA — it must sit alongside PK and PHIA evidence, and IUR values carry their own scientific uncertainty.

Who should NOT rely on ELCR alone: anyone treating it as a standalone pass/fail. It is one evidence element, not the whole submission.

FAQ

What reference cigarette is used?

The 1R6F reference cigarette (University of Kentucky), the current standard reference that succeeded 3R4F.

Where do the unit-risk values come from?

A corrected IUR library based on OEHHA, EPA IRIS and IARC.

References: FDA CTP HPHC guidance and 2024-06 memo; OEHHA; US EPA IRIS; IARC Monographs; University of Kentucky Reference Cigarette Program (1R6F).

See your formula’s evidence today

Run ELCR, in-silico PK and PHIA in your browser — a §1114.7-ready report in hours.

Start free — no signup
← All articles

Disclaimer: PMTA Hub tools generate model-based supporting evidence for regulatory decision-making. They do not constitute, and do not guarantee, FDA or NMPA authorization. Modeled evidence is typically combined with a confirmatory study in a weight-of-evidence submission.